| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/15/2006 | EP1625153A1 Acylated lysobactin-type nonadepsipeptides |
| 02/15/2006 | EP1625152A2 Peptides modulating the activity of the engrailed transcription factor |
| 02/15/2006 | EP1625151A2 Comparative ligand mapping from mhc class i positive cells |
| 02/15/2006 | EP1625145A1 Extraction process for a pharmaceutical product |
| 02/15/2006 | EP1624897A2 Hiv prodrugs cleavable by cd26 |
| 02/15/2006 | EP1624893A2 Inhibitors of phosphodiesterases in infertility |
| 02/15/2006 | EP1624887A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes |
| 02/15/2006 | EP1624886A2 Methods for increasing cell and tissue viability |
| 02/15/2006 | EP1624885A2 Synthetic peptide analogs of arg-pro-pro-gly-phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4 |
| 02/15/2006 | EP1624884A2 Somatostatin vectors |
| 02/15/2006 | EP1624883A2 Compositions and methods related to production of erythropoietin |
| 02/15/2006 | EP1624882A2 Compositions for delivering peptide yy and pyy agonists |
| 02/15/2006 | EP1624850A2 Compositions and methods for treatment of severe acute respiratory syndrome (sars) |
| 02/15/2006 | EP1624847A2 Compositions and methods for the preparation of human growth hormone glycosylation mutants |
| 02/15/2006 | EP1624786A2 Methods for the treatment and prevention of diseases of biological conduits |
| 02/15/2006 | EP1624752A2 Delivery of compounds with rehydrated blood cells |
| 02/15/2006 | EP1578802A4 Dna/rna transduction technology and its clinical and basic applications |
| 02/15/2006 | EP1490088A4 Dentritic cell nodes |
| 02/15/2006 | EP1481057B1 System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 02/15/2006 | EP1399468B1 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| 02/15/2006 | EP1268493B1 Phosphoramidate prodrugs |
| 02/15/2006 | EP1065269B1 Genomic gene encoding hm1.24 antigen protein and promoter thereof |
| 02/15/2006 | EP1003550B1 Receptor specific transepithelial transport of therapeutics |
| 02/15/2006 | EP0791050B1 Vectors for tissue-specific replication |
| 02/15/2006 | CN1735630A Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
| 02/15/2006 | CN1735628A Polypeptides F' of the hepatitis c virus, epitopes, and the diagnostic and therapeutic applications thereof |
| 02/15/2006 | CN1735435A Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 02/15/2006 | CN1735433A Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses |
| 02/15/2006 | CN1735428A Chaperonin 10 immunosuppression |
| 02/15/2006 | CN1735427A Pain relief agents |
| 02/15/2006 | CN1735426A Peptides as solubilizing excipients for transforming growth factor ss proteins |
| 02/15/2006 | CN1735425A Cytomodulating peptides for treating interstitial cystitis |
| 02/15/2006 | CN1735424A Saposin C-DOPS: a novel anti-tumor agent |
| 02/15/2006 | CN1735423A Treatment of gastroparesis |
| 02/15/2006 | CN1735422A Pept¿¼deos antimicrobianos de novispirin |
| 02/15/2006 | CN1735393A Soluble oral patch with collagen and interlaced active ingredients |
| 02/15/2006 | CN1733922A Super antigen fusion protein and its application method |
| 02/15/2006 | CN1733918A Motilin homologs |
| 02/15/2006 | CN1733913A High purity venom kininogenase prepartion method and its pharmaceutical formulation |
| 02/15/2006 | CN1733807A Fusion protein possessing growth facilitation action and its coding gene and uses |
| 02/15/2006 | CN1733801A Extraction method and uses of traditional Chinese medicine cassia seed protein |
| 02/15/2006 | CN1733800A Outer surface proteins, their genes, and their use |
| 02/15/2006 | CN1733798A Hepatitis B virus surface L protein related peptide |
| 02/15/2006 | CN1733311A Process for preparing nanometer fiber for packaging medicine or growth factor |
| 02/15/2006 | CN1733298A Microcapsule type blood substitute based on hemoglobin and process for preparing the same |
| 02/15/2006 | CN1733297A Joint nutrient tablet |
| 02/15/2006 | CN1733296A Stable liquid interferon formulations |
| 02/15/2006 | CN1733295A Externally used solution for recombined human alkaline fibroblast growth factor and process for preparing the same |
| 02/15/2006 | CN1733294A Recombined human alkaline fibroblast growth factor gelling agent and process for preparing the same |
| 02/15/2006 | CN1733293A Cerebroside carnosine freeze-dried powder and process for preparing the same |
| 02/15/2006 | CN1242059C Production of rDSPA 'alpha' I |
| 02/15/2006 | CN1242052C Biological pure culture for Nocardia |
| 02/15/2006 | CN1241946C Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
| 02/15/2006 | CN1241945C Hybrid protein for inhibiting the deatanulation of mastocytes and the use thereof |
| 02/15/2006 | CN1241944C Antibody againts 'alpha'-chain of human interleukin 5 receptor |
| 02/15/2006 | CN1241942C Methods for treatment of diabetes using peptide analogues of insulin |
| 02/15/2006 | CN1241941C Protein for promoting nerve differentiation and resisting cell death, and its coding gene |
| 02/15/2006 | CN1241940C Novel collagen-like protein CLAC, Precursor thereof and genes encoding the same |
| 02/15/2006 | CN1241936C Polypeptide of inhibiting crown virus and its derivant |
| 02/15/2006 | CN1241924C Method for preparing enkephalinase and angiotensin-converting enzyme inhibitor intermediate and its intermediate |
| 02/15/2006 | CN1241646C Improvement in or relating to endometrial function |
| 02/15/2006 | CN1241638C IFNAR2/I FN complex |
| 02/15/2006 | CN1241637C Preparation of extramembranou section of therapeutic protein B lymphocyte stimulation factor |
| 02/15/2006 | CN1241636C Treatment of epidermlyosis bullosa with thymosin Beta-4 |
| 02/15/2006 | CN1241549C Amphoteric liposomes and the use thereof |
| 02/15/2006 | CN1241548C Stable protein: phospholipid composition and method |
| 02/15/2006 | CN1241540C Cosmetic composition comprising human serum albumin obtained from transgenic non-human animals |
| 02/15/2006 | CN1241480C Pesticidal and antiparasitic compositions |
| 02/14/2006 | USRE38984 comprising the use of known antifungal agents such as the azoles or polyenes in combination with a pneumocandin derivative antifungal agent |
| 02/14/2006 | US6998476 Nucleic acids encoding antagonists of interleukin-15 |
| 02/14/2006 | US6998474 used for prevention and/or treatment of pathologies, dysfunctions, disorders or conditions affecting the nervous system |
| 02/14/2006 | US6998469 for treating thrombosis and other vascular diseases |
| 02/14/2006 | US6998423 Sulfonyl-amino or carbonyl-amino derivatives; osteoporosis bone disorders; therapeutic drug or kits including anti-resorptive agents, anabolic agents; |
| 02/14/2006 | US6998410 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide |
| 02/14/2006 | US6998398 use in improvement of gastrointestinal blood flow, in treatment of hypertension and in treatment and prophylaxis of cardiac damages induced by adriamycin and comparable anti-cancer drugs |
| 02/14/2006 | US6998393 Aquespheres, their preparation and uses thereof |
| 02/14/2006 | US6998389 Captopril; hyaluronidases; phospholipases |
| 02/14/2006 | US6998388 High density lipoprotein against organ dysfunction following haemorrhagic shock |
| 02/14/2006 | US6998387 Human appetite control by glucagon-like peptide receptor binding compounds |
| 02/14/2006 | US6998385 Antiinflammatory agents; autoimmune disease |
| 02/14/2006 | US6998384 Surfactant prevention of lung complications from cancer chemotherapy |
| 02/14/2006 | US6998383 Inhibitors of receptor activator of NF-κB and uses thereof |
| 02/14/2006 | US6998268 Gene preparations |
| 02/14/2006 | US6998263 Methods of preparing and using a viral vector library |
| 02/14/2006 | US6998245 Serine protease BSSP5 |
| 02/14/2006 | US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist |
| 02/14/2006 | US6998243 Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons |
| 02/14/2006 | US6998239 contacting an isolated or recombinant CCX CKR polypeptide or, a fragment or variant, and the chemokine in the presence of a test compound, comparing the level of binding of the chemokine and the polypeptide |
| 02/14/2006 | US6998237 GD3 peptide mimics |
| 02/14/2006 | US6998137 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| 02/14/2006 | US6998136 Stability for injection solutions |
| 02/14/2006 | US6998134 Biologically active implants |
| 02/14/2006 | US6998129 Comprises association between elastase inhibitor compound of the N-acylaminoamide family and at least one antiinflammatory compound; for improving skin ageing and/or photoageing signs by slowing down connective tissue alterations |
| 02/14/2006 | US6998123 interleukins (IL-11); fibronectins; glycoproteins |
| 02/14/2006 | US6998122 which retain wild-type biological activity and extend half-lives in human blood; resistant to serpin activation; for treatment of vascular occlusive disorders, hypercoagulable states, and thrombotic disorders |
| 02/14/2006 | US6998121 Treatment of Dupuytren's contracture, scleroderma, Peyronie's disease, bovine mastistis and claudication due to peripheral arterial disease |
| 02/14/2006 | US6998120 which induces the protection mechanisms of plants by releasing cutin monomer (such as 9-octadecenamide, which hydrolyzes cuticles of fruit), generating hydrogen peroxide and expressing pathogenic related genes |
| 02/14/2006 | US6998117 Cancer treatment with retroviral vectors comprising wild-type p53 |
| 02/14/2006 | US6998116 tumor necrosis factor related cytokines which induce apoptosis; for treatment of cancer/glioblastomas |
| 02/14/2006 | US6998115 Biodegradable and biocompatible and may be used in a variety of drug delivery systems; suited for the delivery of polynucleotides |